Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201502-07 Preclinical study of Carbiferon, a next generation IFN-beta, for multiple sclerosis(CNS Diseases, Protein) [09.03.2015]

PRINT

Development and Market Objectives

A biobetter version of recombinant human interferon-β1a (rhIFN-β 1a) has been developed to improve its biophysical properties, such as aggregation, production and stability and pharmacokinetic properties, without jeopardizing its activity. Glycoengineering had no effect on rhIFN-β ligand-receptor binding, as no loss of specific activity was observed. R27T showed improved stability and had a reduced propensity for aggregation and an increased half-life. 
 


Target indication : First line Tx for Relapsing Remitting Multiple Sclerosis (RRMS) & Clinically isolated syndrome (CIS)

Unmet Medical Need & Target Patients

Status

Process Development

♦ Cell Line development
- High producer
- Reduced NGNA vs. NANA content

♦ Culture process development
- High productivity (Basal and feed media optimization)
- Full glycosylation of both sites

♦ Purification process development
- High Purification yield
- Efficient separation of single vs. double glycosylation forms

♦ Overall anticipated productivity improvement : 15 – 50 fold increase

Intellectual Property

Competitive Advantages

Indication

Metabolic Disorder

Research Period

2015.8.10-2017.10.9

Company

ABION Inc.

Developmental Stage

Preclinical

Additional Information

Contact Information

Contact
Address Company Name: ABION Inc.
WebSite Homepage: http://www.abionbio.com Contact Person: Kyoung Song
E-mail: sk17@abionbio.com Contact: +82-2-6006-7631

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code